Microsatellite instability status affects gene expression profiles in early onset colorectal cancer patients

Journal of Surgical Research

Volumn 185, Issue 2, 2013, Pages 626-637

  Ak, Secil ^a   Tunca, Berrin ^a   Yilmazlar, Tuncay ^a   Tezcan, Gulcin ^a   Cecener, Gulsah ^a   Egeli, Unal ^a   Ozturk, Ersin ^a   Yerci, Omer ^a   Ertürk, Elif ^a   Zorluoglu, Abdullah ^b  

^a ULUDAG UNIVERSITY   (Turkey)

^b Acibadem Hospital   (Turkey)

Author keywords

CK20; Colorectal cancer; Early onset; MAP3K8; MSI; MSS; REG1A

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 20; LITHOSTATHINE; MAP3K8 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; ONCOPROTEIN; REG1A PROTEIN, HUMAN; TRANSCRIPTOME; GENETIC MARKER;

ADULT; ARTICLE; BAT25 GENE; BAT26 GENE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CARCINOGENESIS; CK20 GENE; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL CARCINOGENESIS; CONTROLLED STUDY; D17S250 GENE; D2S123 GENE; D5S346 GENE; DISTANT METASTASIS; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION PROFILING; HEREDITY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MAP3K8 GENE; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; MICROSATELLITE STABILITY; MIDDLE AGED; POPULATION GENETIC PARAMETERS; PRIORITY JOURNAL; REG1A GENE; SURVIVAL; TURKEY (REPUBLIC); UPREGULATION; YOUNG ADULT; ADOLESCENT; CK20; COLORECTAL TUMOR; DNA METHYLATION; EARLY ONSET; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETIC SCREENING; GENETICS; MAP3K8; METASTASIS; MORTALITY; MSI; MSS; ONSET AGE; PROGNOSIS; REG1A; SECONDARY;

CK20; COLORECTAL CANCER; EARLY ONSET; MAP3K8; MSI; MSS; REG1A;

ADOLESCENT; ADULT; AGE OF ONSET; COLORECTAL NEOPLASMS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; GENETIC TESTING; HUMANS; KERATIN-20; LITHOSTATHINE; LYMPHATIC METASTASIS; MALE; MAP KINASE KINASE KINASES; MICROSATELLITE INSTABILITY; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS; TRANSCRIPTOME; YOUNG ADULT;

EID: 84891668986     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2013.07.014     Document Type: Article

References (52)

1. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159.
2. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 2003;21:1174.
3. Lynch HT, de la Chapelle A. Genomic medicinedhereditary colorectal cancer. New Engl J Med 2003;348:919.
4. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998;95:6870.
5. Yamamoto H, Adachi Y, Taniguchi H, et al. Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer. World J Gastroenterol 2012;18:2745.
6. Kim HG, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 1994;145:148.
7. Gryfe R, Kim H, Hsieh ETK, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. New Engl J Med 2000;342:69.
8. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609.
9. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247.
10. Lanza G, Ferracin M, Gafa R, et al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer 2007;6:54.
11. Mori Y, Yin J, Sato F, et al. Identification of genes uniquely involved in frequent microsatellite instability colon carcinogenesis by expression profiling combined with epigenetic scanning. Cancer Res 2004;64:2434.
12. Banerjea A, Ahmed S, Hands RE, et al. Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity. Mol Cancer 2004;3:21.
13. Kim H, Nam SW, Rhee H, et al. Different gene expression profiles between microsatellite instability-high and microsatellite stable colorectal carcinomas. Oncogene 2004; 23:6218.
14. Giacomini CP, Leung SY, Chen X, et al. A gene expression signature of genetic instability in colon cancer. Cancer Res 2005;65:9200.
15. Kruhoffer M, Jensen JL, Laiho P, et al. Gene expression signatures for colorectal cancer microsatellite status and HNPCC. Br J Cancer 2005;92:2240.
16. Tunca B, Tezcan G, Cecener G, et al. Overexpression of CK20, MAP3K8 and EIF5A correlates with poor prognosis in early-onset colorectal cancer patients. J Cancer Res Clin Oncol 2013;139:691.
17. Losi L, Di Gregorio C, Pedroni M, et al. Molecular genetic alterations and clinical features in early-onset colorectal carcinomas and their role for the recognition of hereditary cancer syndromes. Am J Gastroenterol 2005;100:2280
18. Turkish Ministry of Health, (2006) http://www.saglik.gov.tr.
19. Boardman LA. Overexpression of MACC1 leads to downstream activation of HGF/MET and potentiates metastasis and recurrence of colorectal cancer. Genome Med 2009;1:36.
20. Jovov B, Araujo-Perez F, Sigel CS, et al. Differential gene expression between African American and European American colorectal cancer patients. PLoS One 2012;7.
21. Perea J, Alvaro E, Rodriguez Y, et al. Approach to early-onset colorectal cancer: clinicopathological, familial, molecular and immunohistochemical characteristics. World J Gastroenterol 2010;16:3697.
22. Murphy WM. Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol 1990;21:886.
23. Moll R, Lowe A, Laufer J, Franke WW. Cytokeratin-20 in human carcinomasda new histodiagnostic marker detected by monoclonal-antibodies. Am J Pathol 1992;140:427.
24. McGregor DK, Wu TT, Rashid A, et al. Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability. Am J Surg Pathol 2004; 28:712.
25. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002;40:403.
26. Lassmann S, Bauer M, Rosenberg R, et al. Identification of occult tumor cells in node negative lymph nodes of colorectal cancer patients by cytokeratin 20 gene and protein expression. Int J Colorectal Dis 2004;19:87.
27. Tatsumi N, Mukaisho KI, Mitsufuji S, et al. Expression of cytokeratins 7 and 20 in serrated adenoma and related diseases. Dig Dis Sci 2005;50:1741.
28. Harnden P, Mahmood N, Southgate J. Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet 1999;353:974.
29. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010;468:968.
30. Jeong JH, Bhatia A, Toth Z, et al. TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth. PLoS One 2011;6.
31. Krcova Z, Ehrmann J, Krejci V, et al. Tpl-2/Cot and Cox-2 in breast cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008;152:21.
32. Alves CA, Silva IDCG, Villanova FE, et al. Differential gene expression profile reveals overexpression of MAP3K8 in invasive endometrioid carcinoma. Eur J Gynaecol Oncol 2006; 27:589.
33. Dumitru CD, Ceci JD, Tsatsanis C, et al. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 2000;103:1071.
34. Das S, Cho J, Lambertz I, et al. Tpl2/Cot signals activate ERK, JNK, and NF-kappa B in a cell-type and stimulus-specific manner. J Biol Chem 2005;280:23748.
35. Astrosini C, Roeefzaad C, Dai YY, et al. REG1A expression is a prognostic marker in colorectal cancer and associated with peritoneal carcinomatosis. Int J Cancer 2008;123:409.
36. Zenilman ME, Kim S, Levine BA, et al. Ectopic expression of reg protein: a marker of colorectal mucosa at risk for neoplasia. J Gastrointest Surg 1997;1:194.
37. Rechreche H, Montalto G, Mallo GV, et al. pap, reg I alpha and reg I beta mRNAs are concomitantly up-regulated during human colorectal carcinogenesis. Int J Cancer 1999;81:688.
38. Lee WS, Seo G, Shin HJ, et al. Identification of differentially expressed genes in microsatellite stable HNPCC and sporadic colon cancer. J Surg Res 2008;144:29-35.
39. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994;73:2013.
40. Dhar DK, Udagawa J, Ishihara S, et al. Expression of regenerating gene I in gastric adenocarcinomas-correlation with tumor differentiation status and patient survival. Cancer 2004;100:1130.
41. Macadam RCA, Sarela A, Farmery SM, et al. Death from early colorectal cancer is predicted by the presence of transcripts of the REG gene family. Br J Cancer 2000;83:188.
42. Xie MJ, Motoo Y, Iovanna JL, et al. Overexpression of pancreatitis-associated protein (PAP) in human pancreatic ductal adenocarcinoma. Dig Dis Sci 2003;48:459.
43. Oue N, Mitani Y, Aung PP, et al. Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. J Pathol 2005;207:185.
44. Harada K, Zen Y, Kanemori Y, et al. Human REG I gene is up-regulated in intrahepatic cholangiocarcinoma and its precursor lesions. Hepatology 2001;33:1036.
45. Violette S, Poulain L, Dussaulx E, et al. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-x(L) in addition to Bax and p53 status. Int J Cancer 2002;98:498.
46. Bishnupuri KS, Luo QZ, Murmu N, et al. Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas. Gastroenterology 2006; 130:137.
47. Ng K, Schrag D. Microsatellite instability and adjuvant fluorouracil chemotherapy: a mismatch? J Clin Oncol 2010; 28:3207.
48. Gustavsson B, Kaiser C, Carlsson G, et al. Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes. Int J Cancer 2009;124:1220.
49. Kim ST, Lee J, Park SH, et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol 2010;66:659.
50. Sargent DJ. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010;28:4664.
51. Tajima A, Hess MT, Cabrera BL, et al. The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: Implications for chemosensitivity and resistance. Gastroenterology 2004;127:1678.
52. Liang JT, Huang KC, Cheng AL, et al. Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age. Br J Surg 2003;90:205.